Form 4: Skye Bioscience Chief Development Officer Sells Shares to Cover Tax Obligations

Skye Bioscience's Chief Development Officer, Tuan Tu Diep, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• Tuan Tu Diep, Chief Development Officer of Skye Bioscience, sold a total of 19,574 shares of common stock.
• The sales were executed on November 15, 2024, and November 18, 2024.
• The first sale of 85 shares was at a price of $5.55 per share.
• The second sale of 19,489 shares was at a weighted average price of $4.99 per share, with individual transactions ranging from $4.98 to $5.08.
• These sales were to cover tax withholding obligations associated with the vesting of performance-based restricted stock units and were not discretionary transactions.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not a significant event that would indicate a positive or negative sentiment. It is a neutral event.

Risks

• Sales by company officers can sometimes be perceived negatively by the market, even if they are for tax purposes.

Management Comments

• The sales were to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary transactions by the Reporting Person.

Industry Context

Insider sales are a common occurrence, especially when executives receive stock-based compensation. These transactions are often planned to cover tax liabilities and are not necessarily indicative of a negative outlook on the company's future.

Comparison to Industry Standards

• It is common for executives at publicly traded companies to sell shares to cover tax obligations related to stock-based compensation.
• The 'sell to cover' method is a standard practice to manage tax liabilities without requiring executives to use personal funds.
• The price range of $4.98 to $5.55 is within the typical range of price fluctuations for a stock like SKYE.

Stakeholder Impact

• The stock sales may have a minor impact on the share price, but are unlikely to have a significant impact on other stakeholders.

Key Dates

Keywords

insider trading, stock sale, tax obligations, restricted stock units, Skye Bioscience, SKYE, Chief Development Officer, Tuan Tu Diep